Drug intelligence / Profile preview

SKW05

Development stage: Preclinical
Lead developer: Skye Biologics

Overview

SKW05 is a biological therapeutic candidate developed by Skye Biologics, specifically designed for nerve regeneration and pain reduction in patients suffering from neuropathy. As part of Skye's "2nd Generation" biological therapeutics, it utilizes naturally advanced human biological materials to promote tissue repair and healing. The therapy aims to address the underlying structural damage in neuropathic conditions to restore nerve function and alleviate chronic pain, rather than merely managing symptoms. It is currently in the early stages of development within Skye Biologics' regenerative medicine pipeline.

Beyond the preview

Go deeper on SKW05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKW05.

Explore the full profile